EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy

Dion Groothof, Mervin de Vries, Nicole S Erler, Reinold O B Gans, Stephan J L Bakker

The Lancet Primary Care · 2026-08 · 2 (8) · 100200

DOI: 10.1016/j.lanprc.2026.100200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Primary Care, 2026-08. Verfasst von Dion Groothof und 4 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In their Article published in The Lancet Primary Care, Thijs T Jansz and colleagues1 reported lower risk of a composite outcome of kidney disease progression (≥40% estimated glomerular filtration rate [eGFR] decline, end-stage kidney disease, or death from kidney-related causes) after initiating GLP-1 receptor agonist treatment in individuals with type 2 diabetes already receiving SGLT2 inhibitor treatment compared with that observed after initiating either DPP-4 inhibitors or sulfonylureas. The findings were consistent across the continuum of kidney disease and therefore interpreted as supporting combined SGLT2 inhibitor and GLP-1 receptor agonist therapy for kidney protection.

Zitieren

APA

Groothof, D., Vries, M. D., Erler, N. S., Gans, R. O. B., & Bakker, S. J. L. (2026). Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy. The Lancet Primary Care, 2(8), 100200. https://doi.org/10.1016/j.lanprc.2026.100200

Vancouver

Groothof D, Vries MD, Erler NS, Gans ROB, Bakker SJL. Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy. The Lancet Primary Care. 2026;2(8):100200. doi:10.1016/j.lanprc.2026.100200

BibTeX
@article{Groothof2026,
  author = {Groothof, Dion and Vries, Mervin de and Erler, Nicole S and Gans, Reinold O B and Bakker, Stephan J L},
  title = {Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy},
  journal = {The Lancet Primary Care},
  year = {2026},
  volume = {2},
  number = {8},
  pages = {100200},
  doi = {10.1016/j.lanprc.2026.100200}
}
Kostenlos starten →